1
|
Ishihara N, Yamashita S, Seiki S, Tsutsui K, Kato-Hayashi H, Sakurai S, Niwa K, Kawai T, Kai J, Suzuki A, Hayashi H. Evaluation of Steroid-Induced Osteoporosis Prevention Using Tracing Reports in Collaboration between Hospitals and Community Pharmacists. PHARMACY 2024; 12:80. [PMID: 38804472 PMCID: PMC11130855 DOI: 10.3390/pharmacy12030080] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/09/2024] [Revised: 05/01/2024] [Accepted: 05/13/2024] [Indexed: 05/29/2024] Open
Abstract
Glucocorticoid-induced osteoporosis (GIOP) is a side effect of glucocorticoid (GC) treatment; however, despite established prevention guidelines in various countries, a gap persists between these guidelines and clinical practice. To address this gap, we implemented a collaborative intervention between hospitals and community pharmacists, aiming to assess its effectiveness. Pharmacists recommended to the prescribing doctor osteoporosis treatment for patients who did not undergo osteoporosis treatment with a fracture risk score of ≥3 via tracing reports (TRs), between 15 December 2021, and 21 January 2022. Data were extracted from electronic medical records, including prescriptions, concomitant medications, reasons for not pursuing osteoporosis treatment, and TR contents. Of 391 evaluated patients, 45 were eligible for TRs, with 34 (75.6%) being males. Prednisolone was the most common GCs administered, and urology was the predominant treatment department. Among the 45 patients who received TRs, prescription suggestions were accepted for 19 (42.2%). After undertaking the intervention, guideline adherence significantly increased from 87% to 92.5%. This improvement indicates that TRs effectively bridged the evidence-practice gap in GIOP prevention among GC patients, suggesting their potential utility. Expansion of this initiative is warranted to further prevent GIOP.
Collapse
Affiliation(s)
- Nonoko Ishihara
- Laboratory of Home Team Care Pharmacy, Gifu Pharmaceutical University, 1-25-4 Daigaku Nishi, Gifu 501-1196, Gifu, Japan; (N.I.); (J.K.)
| | - Shuji Yamashita
- Laboratory of Community Pharmaceutical Practice and Science, Gifu Pharmaceutical University, 1-25-4 Daigaku Nishi, Gifu 501-1196, Gifu, Japan; (S.Y.); (S.S.); (K.T.)
| | - Shizuno Seiki
- Laboratory of Community Pharmaceutical Practice and Science, Gifu Pharmaceutical University, 1-25-4 Daigaku Nishi, Gifu 501-1196, Gifu, Japan; (S.Y.); (S.S.); (K.T.)
| | - Keito Tsutsui
- Laboratory of Community Pharmaceutical Practice and Science, Gifu Pharmaceutical University, 1-25-4 Daigaku Nishi, Gifu 501-1196, Gifu, Japan; (S.Y.); (S.S.); (K.T.)
| | - Hiroko Kato-Hayashi
- Department of Pharmacy, Gifu University Hospital, 1-1 Yanagido, Gifu 501-1194, Gifu, Japan; (H.K.-H.); (S.S.); (K.N.); (A.S.)
| | - Shuji Sakurai
- Department of Pharmacy, Gifu University Hospital, 1-1 Yanagido, Gifu 501-1194, Gifu, Japan; (H.K.-H.); (S.S.); (K.N.); (A.S.)
| | - Kyoko Niwa
- Department of Pharmacy, Gifu University Hospital, 1-1 Yanagido, Gifu 501-1194, Gifu, Japan; (H.K.-H.); (S.S.); (K.N.); (A.S.)
| | - Takuyoshi Kawai
- Laboratory of Community Healthcare Pharmacy, Gifu Pharmaceutical University, 1-25-4 Daigaku Nishi, Gifu 501-1196, Gifu, Japan;
| | - Junko Kai
- Laboratory of Home Team Care Pharmacy, Gifu Pharmaceutical University, 1-25-4 Daigaku Nishi, Gifu 501-1196, Gifu, Japan; (N.I.); (J.K.)
| | - Akio Suzuki
- Department of Pharmacy, Gifu University Hospital, 1-1 Yanagido, Gifu 501-1194, Gifu, Japan; (H.K.-H.); (S.S.); (K.N.); (A.S.)
- Laboratory of Advanced Medical Pharmacy, Gifu Pharmaceutical University, 1-25-4 Daigaku Nishi, Gifu 501-1196, Gifu, Japan
| | - Hideki Hayashi
- Laboratory of Home Team Care Pharmacy, Gifu Pharmaceutical University, 1-25-4 Daigaku Nishi, Gifu 501-1196, Gifu, Japan; (N.I.); (J.K.)
- Laboratory of Community Pharmaceutical Practice and Science, Gifu Pharmaceutical University, 1-25-4 Daigaku Nishi, Gifu 501-1196, Gifu, Japan; (S.Y.); (S.S.); (K.T.)
- Department of Pharmacy, Gifu University Hospital, 1-1 Yanagido, Gifu 501-1194, Gifu, Japan; (H.K.-H.); (S.S.); (K.N.); (A.S.)
- Laboratory of Community Healthcare Pharmacy, Gifu Pharmaceutical University, 1-25-4 Daigaku Nishi, Gifu 501-1196, Gifu, Japan;
| |
Collapse
|
2
|
The Treatment Gap in Osteoporosis. J Clin Med 2021; 10:jcm10133002. [PMID: 34279485 PMCID: PMC8268346 DOI: 10.3390/jcm10133002] [Citation(s) in RCA: 30] [Impact Index Per Article: 10.0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/29/2021] [Revised: 06/28/2021] [Accepted: 07/02/2021] [Indexed: 11/17/2022] Open
Abstract
Worldwide, there are millions of people who have been diagnosed with osteoporosis, a bone disease that increases the risk of fracture due to low bone mineral density and deterioration of bone architecture. In the US alone, there are approximately ten million men and women diagnosed with osteoporosis and this number is still growing. Diagnosis is made by measuring bone mineral density. Medications used for the treatment of osteoporosis are bisphosphonates, denosumab, raloxifene, and teriparatide. Recently, romosozumab has been added as well. In recent years, a number of advances have been made in the field of diagnostic methods and the diverse treatment options for osteoporosis. Despite these advances and a growing incidence of osteoporosis, there is a large group being left undertreated or even untreated. This group of the under/untreated has been called the treatment gap. Concerns regarding rare side effects of the medications, such as osteonecrosis of the jaw, have been reported to be one of the many causes for the treatment gap. Also, this group seems not to be sufficiently informed of the major benefits of the treatment and the diversity in treatment options. Knowledge of these could be very helpful in improving compliance and hopefully reducing the gap. In this paper, we summarize recent evidence regarding the efficacy of the various treatment options, potential side effects, and the overall benefit of treatment.
Collapse
|
3
|
Kaplan RL, Albers JW. Treatment of chronic inflammatory demyelinating polyneuropathy. Expert Rev Neurother 2014; 3:233-46. [DOI: 10.1586/14737175.3.2.233] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/08/2022]
|
4
|
Devogelaer JP, Sambrook P, Reid DM, Goemaere S, Ish-Shalom S, Collette J, Su G, Bucci-Rechtweg C, Papanastasiou P, Reginster JY. Effect on bone turnover markers of once-yearly intravenous infusion of zoledronic acid versus daily oral risedronate in patients treated with glucocorticoids. Rheumatology (Oxford) 2013; 52:1058-69. [DOI: 10.1093/rheumatology/kes410] [Citation(s) in RCA: 14] [Impact Index Per Article: 1.3] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/13/2022] Open
|
5
|
Primary prophylaxis for steroid-induced osteoporosis: Are we doing enough?–An audit from a tertiary care centre. INDIAN JOURNAL OF RHEUMATOLOGY 2010. [DOI: 10.1016/s0973-3698(11)60005-8] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
|
6
|
Abstract
BACKGROUND The burden of osteoporosis is on the rise and glucocorticoids are one of the leading causes of drug-induced osteoporosis. According to available guidelines, patients on long-term glucocorticoid therapy should receive adequate prophylaxis to prevent osteoporosis. OBJECTIVES To compare prescription patterns in relation to Royal College of Physicians (RCP) Guidelines 2002. To identify prescribing trends for prophylaxis and management of steroid-induced osteoporosis. METHODS We conducted a retrospective audit for patients in a tertiary care center to determine whether clinicians are evaluating and appropriately following prophylactic guidelines for corticoid-induced osteoporosis. Information regarding risk assessment for osteoporosis, instructions regarding its prevention, bone mineral density measurements, and prophylactic therapy were recorded. RESULTS One hundred and five patients (38 men and 67 women), more then 18 years of age were included in this study. Of the 105 patients, 56% had at least one documented intervention for osteoporosis prevention (calcium, vitamin D, bisphosphonates or a bone mineral density study). Only three patients received bisphosphonates for osteoporosis prophylaxis. CONCLUSION The study shows poor pre-therapeutic risk assessment, absence of instructions regarding preventive measures, inappropriate investigation for presence of osteoporosis, and unacceptable absence of bone protective agents.
Collapse
Affiliation(s)
- Chanchal Gera
- Department of Medicine, Christian Medical College & Hospital, Ludhiana, Punjab.
| | | |
Collapse
|
7
|
Walker RA, Hall RB, Pekush RD, Taylor-Gjevre RM. Osteoporosis prophylaxis prescribing patterns in ophthalmology patients treated with long-term corticosteroids. Can J Ophthalmol 2010; 45:81-2. [PMID: 20130720 DOI: 10.3129/i09-169] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/01/2022]
|
8
|
Sadat-Ali M, Alelq AH, Alshafei BA, Al-Turki HA, Abujubara MA. Osteoporosis prophylaxis in patients receiving chronic glucocorticoid therapy. Ann Saudi Med 2009; 29:215-8. [PMID: 19448373 PMCID: PMC2813647 DOI: 10.5144/0256-4947.2009.215] [Citation(s) in RCA: 11] [Impact Index Per Article: 0.7] [Reference Citation Analysis] [Abstract] [Track Full Text] [Download PDF] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/22/2022] Open
Abstract
BACKGROUND AND OBJECTIVES Glucocorticoid-induced osteoporosis (GIOP) is the most common form of secondary osteoporosis, yet few patients receive proper measures to prevent its development. We retrospectively searched prescription records to determine if patients receiving oral prednisolone were receiving prophylaxis or treatment for osteopenia and osteoporosis. METHODS Patients who were prescribed > or =7.5 milligrams of prednisolone for 6 months or longer during a 6- month period were identified through the prescription monitoring system. Demographic and clinical data were extracted from the patient records, and dual energy x-ray absorptiometry (DEXA) scans were retrieved, when available. Use of oral calcium, vitamin D and anti-resorptives was recorded. RESULTS One hundred males and 65 females were receiving oral prednisolone for a mean (SD) duration of 40.4 (29.9) months in males and 41.2 (36.4) months in females. Twenty-one females (12.7%) and 5 (3%) males had bone mineral density measured by DEXA. Of those, 10 (47.6%) females and 3 (50%) males were osteoporotic and 11(52.4%) females and 2 (40%) males were osteopenic. Calcium and vitamin D were prescribed to the majority of patients (60% to 80%), but none were prescribed antiresorptive/anabolic therapy. CONCLUSIONS Patients in this study were neither investigated properly nor treated according to the minimum recommendations for the management of GIOP. Physician awareness about the prevention and treatment of GIOP should be a priority for the local health care system.
Collapse
Affiliation(s)
- Mir Sadat-Ali
- Department of Orthopedic Surgery, King Faisal University, Saudi Arabia.
| | | | | | | | | |
Collapse
|
9
|
Duyvendak M, Naunton M, van Roon EN, Bruyn GAW, Brouwers JRBJ. Systematic review of trends in prophylaxis of corticosteroid-induced osteoporosis: the need for standard audit guidelines. Osteoporos Int 2008; 19:1379-94. [PMID: 18629573 DOI: 10.1007/s00198-008-0598-y] [Citation(s) in RCA: 6] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 10/16/2007] [Accepted: 02/18/2008] [Indexed: 10/21/2022]
Abstract
UNLABELLED Corticosteroid-induced osteoporosis (CIOP) is currently undertreated. Systematic review of the literature revealed that the percentage of patients treated adequately is dependent on study quality. Therefore, it remains unknown whether adherence to the guidelines is really so poor. Five major quality criteria provide the standard for future studies on this scope. INTRODUCTION It has recently been stated that the degree of prophylaxis of corticosteroid-induced osteoporosis (CIOP) is low and effort should be put into determining reasons for non-prescribing of preventive agents. The aim of this study was to identify: how many studies adequately audit the prevalent guideline; the longitudinal trends in prevention of CIOP; which patient groups appear to be most undertreated; and which intervention strategies are effective. METHODS We performed a comprehensive search of MEDLINE and systematically recorded the outcomes and quality of published studies, using five major criteria. RESULTS Twenty-four studies were included in the analysis. The quality of the included studies was poor (31%) or moderate (37%). There was a longitudinal increase in quality of the studies and percentage of prevention. Multivariable linear regression showed that the quality of the study was the only independent predictor of the prevention rate reported in the study. CONCLUSIONS The results show undertreatment of CIOP might be due to insufficient quality of the studies rather than poor practice or failure to recognise the right patients. Future interventions should comply with five major quality criteria, and a multifaceted approach is required in order to make an impact on the underprescribing of CIOP prophylaxis.
Collapse
Affiliation(s)
- M Duyvendak
- Department of Pharmacotherapy and Pharmaceutical Care, University of Groningen, Ant. Deusinglaan 1, 9713 AV, Groningen, The Netherlands.
| | | | | | | | | |
Collapse
|
10
|
|
11
|
Liu RH, Werth VP. What is new in the treatment of steroid-induced osteoporosis? SEMINARS IN CUTANEOUS MEDICINE AND SURGERY 2006; 25:72-8. [PMID: 16908396 DOI: 10.1016/j.sder.2006.04.003] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 05/11/2023]
Abstract
Glucocorticoid-induced osteoporosis (GIOP) is a serious complication resulting from long-term steroid treatment. In addition to several nonpharmacologic therapies recommended by the American College of Rheumatology, various pharmacologic therapies, such as calcium, vitamin D, hormone-replacement therapy, calcitonin, and bisphosphonates, can be used to prevent and/or treat GIOP. Bisphosphonates, which are potent inhibitors of bone resorption, are considered the most effective and first-line agents for increasing bone mineral density and decreasing the risk of fracture. Human parathyroid hormone has emerged as a promising agent for the treatment of severe GIOP when used alone or in combination with a bisphosphonate.
Collapse
Affiliation(s)
- Rosemarie H Liu
- Department of Internal Medicine, Yale-New Haven Hospital, New Haven, CT, USA
| | | |
Collapse
|
12
|
Are Patients on Long-Term Corticosteroids Receiving Bone Loss Therapy? JOURNAL OF PHARMACY PRACTICE AND RESEARCH 2006. [DOI: 10.1002/j.2055-2335.2006.tb00882.x] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/07/2022]
|
13
|
Loddenkemper K, Bohl N, Perka C, Burmester GR, Buttgereit F. Correlation of different bone markers with bone density in patients with rheumatic diseases on glucocorticoid therapy. Rheumatol Int 2005; 26:331-6. [PMID: 15887044 DOI: 10.1007/s00296-005-0608-8] [Citation(s) in RCA: 7] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/19/2004] [Accepted: 02/05/2005] [Indexed: 11/28/2022]
Abstract
Osteoporosis is a common concomitant disease in patients with rheumatic diseases on glucocorticoid (GC) therapy. Bone status is usually evaluated by determination of bone density in combination with clinical examinations and laboratory tests. However, the strength of individual biochemical bone makers in GC-induced osteoporosis has yet to be fully clarified. For this reason, different bone markers were investigated in correlation with bone density in patients with rheumatic diseases. Approximately 238 patients (212 women, 26 men) with a rheumatic disease and under GC therapy were examined consecutively for the first time with regard to bone density (BMD) and bone markers [osteocalcin, bone-specific alkaline phosphatase (precipitation method/tandem-MP ostase), crosslinks [pyridinoline (PYD), deoxypyridinoline (DPX), N-terminal telopeptide (NTX)]]. The daily glucocorticoid dose was 10 mg prednisone equivalent (median), and the cumulative dose was 12 g prednisone equivalent (median). None of the patients had previously taken medication for osteoporosis. Osteoporosis was demonstrated in 35.3% of the patients, osteopenia in 47.5%, and a normal BMD in 17.2%. The results of tandem-MP ostase correlated with the BMD of the lumbar spine and of the femoral neck. The values for N-terminal telopeptide and pyridinoline correlated only with the bone density of the femoral neck. All results were statistically significant, although the correlation coefficients were low. After classification of the patients according to their BMD values (osteoporosis, osteopenia and normal BMD), there were significantly more patients with bone markers above the norm in the osteoporosis group and in the osteopenia group than in the group with normal bone density. All bone markers recorded behaved similarly in relation to the bone density values. The same analysis was also undertaken for the different disease groups. In these subgroups there was also a correlation between ostase/crosslinks with BMD, but the correlation coefficients were low. A general recommendation for the routine use of a specific bone marker in patients with rheumatic diseases on glucocorticoid therapy cannot be made from a cost-benefit point of view mainly because of limited predictive power (low correlation coefficients, incomplete correlation with different sites of BMD measurement).
Collapse
Affiliation(s)
- Konstanze Loddenkemper
- Department of Rheumatology and Clinical Immunology, Charité-Universitätsmedizin Berlin Campus Charité-Mitte, Charité University Hospital, Schumannstrasse 20/21, 10117 Berlin, Germany.
| | | | | | | | | |
Collapse
|
14
|
Ryan JG, Morgan RK, Lavin PJ, Murray FE, O'Connell PG. Current management of corticosteroid-induced osteoporosis: variations in awareness and management. Ir J Med Sci 2004; 173:20-2. [PMID: 15732231 DOI: 10.1007/bf02914518] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/29/2022]
Abstract
BACKGROUND Guidelines for the prevention of corticosteroid-induced osteoporosis (CIO) have been widely published. There are no guidelines on the use of gastro-protectants with corticosteroids (CS). AIMS To determine whether patients receiving CS therapy are evaluated and treated for osteoporosis risk, how management varied by steroid dose and diagnosis, and how many patients received gastro-protection. METHODS A retrospective audit of 4,350 patients presenting to four medical specialities. RESULTS One hundred and fifty-one patients prescribed CS were identified. Indications for CS therapy included renal transplantation (32%) and asthma/respiratory diseases (23%), inflammatory arthritis/vasculitis (32%) and inflammatory bowel disease/auto-immune hepatitis/other (13%). Risk of osteoporosis was mentioned in 13% of charts. The prescription rates for bone protection agents varied from 69% to 4% according to the medical speciality attended. Gastro-protectants were prescribed for 44% of patients. CONCLUSION There are large variations among medical specialties both in the prescription of gastro-protectant agents and in the use of measures to prevent CIO. Simpler guidelines could facilitate rational prescribing in these patients.
Collapse
Affiliation(s)
- J G Ryan
- Department of Rheumatology, Beaumont Hospital and Royal College of Surgeons in Ireland, Dublin, Ireland
| | | | | | | | | |
Collapse
|
15
|
Abstract
Corticosteroid-induced osteoporosis is the leading cause of secondary osteoporosis and a significant cause of morbidity in both men and women. Long-term use of even low-dose corticosteroids has been associated with increased risk of bone loss. Recent large randomized controlled trials have generated new knowledge on treatment strategies for patients with corticosteroid-induced osteoporosis. However, the majority of individuals receiving corticosteroids are not receiving prophylaxis for osteoporosis. Calcium and vitamin D should be recommended to patients initiating therapy with corticosteroids (and should be adequate for those receiving corticosteroids for less than 3 months). For those receiving corticosteroids for greater than 3 months, bisphosphonates are the therapy of choice, with both alendronate (alendronic acid) and risedronate (risedronic acid) approved by the US FDA for use in this indication. Calcitonin can be considered a second-line agent and should be reserved for patients who are intolerant of bisphosphonates or who are experiencing pain from a vertebral fracture. Hormone replacement therapy or testosterone therapy may be offered to those individuals on long-term corticosteroid treatment who are hypogonadal. Teriparatide (recombinant human parathyroid hormone 1-34) shows promise as a future anabolic agent for the prevention and treatment of patients with corticosteroid-induced osteoporosis.
Collapse
Affiliation(s)
- Ann Cranney
- Queen's University, Kingston, Ontario, Canada
| | | |
Collapse
|